GO
Loading...

Enter multiple symbols separated by commas

Biotechnology

More

  • US earnings: 'Tech to the rescue'   Thursday, 29 Jan 2015 | 5:00 AM ET
    US earnings: 'Tech to the rescue'

    Caterpillar and 3Ms' poor earnings performance "spooked investors", however tech and healthcare are expected to save the earnings season, says Christine Short, senior vice president at Estimize.

  • The rise and rise of biotech stocks?   Friday, 16 Jan 2015 | 5:20 AM ET
    The rise and rise of biotech stocks?

    Biotech stocks in the U.S. have outperformed significantly over the last three years -- and this can continue, says Matthew Roden, executive director of biotechnology equity research at UBS AG.

  • Biopharma's challenges in 2015   Wednesday, 14 Jan 2015 | 9:30 AM ET
    Biopharma's challenges in 2015

    Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.

  • I am a better person: Sam Waksal   Tuesday, 13 Jan 2015 | 8:36 AM ET
    I am a better person: Sam Waksal

    Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.

  • I'm not running the show: Sam Waksal   Tuesday, 13 Jan 2015 | 8:33 AM ET
    I'm not running the show: Sam Waksal

    CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discusses his role in the company.

  • Sam Waksal's IPO biotech plans   Tuesday, 13 Jan 2015 | 8:31 AM ET
    Sam Waksal's IPO biotech plans

    CNBC's Meg Tirrell, and Sam Waksal, Kadmon founder & chairman, discuss plans to take the biotech company public.

  • Biogen Idec beefs up pain pipeline   Monday, 12 Jan 2015 | 3:16 PM ET
    Biogen Idec beefs up pain pipeline

    Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.

  • 23andMe partners with big pharma   Monday, 12 Jan 2015 | 12:20 PM ET
    23andMe partners with big pharma

    Anne Wojcicki, co-founder and CEO of genetic-testing startup 23andMe, discusses the new deals with Pfizer and Genentech.

  • Celgene CEO: Creating a great future   Monday, 12 Jan 2015 | 11:45 AM ET
    Celgene CEO: Creating a great future

    CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.

  • Analyzing Eli Lilly's drug pipeline   Monday, 12 Jan 2015 | 10:15 AM ET
    Analyzing Eli Lilly's drug pipeline

    CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.

  • Stock moving information kept behind doors   Thursday, 8 Jan 2015 | 2:37 PM ET
    Stock moving information kept behind doors

    CNBC's Meg Tirrell provides insight to the debate over transparency from biotech companies. Biotech investor Brad Loncar, thinks this is just an awareness issue.

  • Jim Cramer's top 10 biotech players   Tuesday, 6 Jan 2015 | 6:15 PM ET
    Cramer: This sector was up 33% last year

    The biotechs were one of the best performing sectors for 2014. Can it work wonders for 2015? Cramer gives his top players in the biotech space.

  • Biotech's strong pipeline   Tuesday, 6 Jan 2015 | 5:45 PM ET
    Biotech's strong pipeline

    A total of 71 biotech companies went public in 2014. Cowen Group President and Cowen & Company CEO Jeffrey Solomon, discusses the market sentiment toward the sector.

  • Will biotech bull run continue?   Tuesday, 6 Jan 2015 | 10:43 AM ET
    Will biotech bull run continue?

    Discussing the outlook on the pharmaceutical sector, including leaders like Gilead and Celgene, with Michael Yee, RBC Capital Markets biotech analyst.

  • Gilead pops, AbbVie drops   Monday, 5 Jan 2015 | 2:50 PM ET
    Gilead pops, AbbVie drops

    Gilead Sciences is lifting the biotech sector higher in today's trade, reports CNBC's Meg Tirrell.

  • Biotech dips mid-year, then you buy: Pro   Wednesday, 31 Dec 2014 | 5:31 PM ET
    Biotech dips mid-year, then you buy: Pro

    Biotech finished 2014 up 44 percent. David Seaburg, thinks biotech will outperform the S&P 500 this year, but there could be some suffering mid-year.

  • 'Mammoth' IPOs send momentum into 2015: Analyst Tuesday, 30 Dec 2014 | 12:54 PM ET
    Alibaba IPO biggest, Alibaba shares, invest in Alibaba, is Alibaba a buy, Alibaba IPO,

    IPO momentum should continue into 2015 after an active 2014 when huge offerings hit like "mammoths from the sky," an analyst said.

  • Want big results? Go small   Monday, 29 Dec 2014 | 10:25 AM ET
    Want big results? Go small

    CNBC's Dominic Chu takes a look at the biggest winners of the market rally and digs into the massive year-end surge for small caps.

  • Bullish on biotech   Monday, 29 Dec 2014 | 7:18 AM ET
    Bullish on biotech

    Eric Schmidt, Cowen & Company senior analyst, predicts the biotech sector will outperform the S&P 500 next year.

  • Mini rebound in biotechs   Wednesday, 24 Dec 2014 | 10:42 AM ET
    Mini rebound in biotechs

    CNBC's Meg Tirrell provides insight to the selloff in biotech stocks after Express Scripts announced it will exclusively cover AbbVie's hepatitis C drug.